Confo Therapeutics
Cedric Ververken (ir.Ph.D.) - CEO, joined Confo Therapeutics in October 2016 from Ablynx NV where he was Vice President Business Development and played a key role in landmark deals for Ablynx. Prior to moving to business development he worked through various R&D functions at Ablynx, first as a scientist in the pharmacology group and later as project manager, leading cross-functional project teams from discovery up to Phase II clinical studies. He therefore brings over 10 years of R&D and business development experience to valorize Confo Therapeutics’ assets and technology.
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.